ArticleArchives of microbiology2026
Probiotic potential and immunomodulatory effects of a thermophilic Bacillus sp. isolated from a hydrothermal vent.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Antibiotic resistance has intensified the need for alternatives, and probiotics offer a natural strategy by enhancing host immunity. The present study investigated the probiotic potential of Bacillus sp. 475B, a strain isolated from a high-temperature hydrothermal vent. In vitro assessments included its safety profile (cytotoxicity, hemolytic activity, and antibiotic susceptibility), tolerance to gastrointestinal and physicochemical stressors, antimicrobial activity, and gut adherence capacity. Additionally, the immunomodulatory effects of Bacillus sp. 475B were evaluated in mice supplemented daily (1 × 10⁸ CFU). Splenocytes were isolated on days 5 and 10, challenged ex vivo with Escherichia coli, and analyzed for immunological assays. Serum and fecal IgA and IgG levels were also quantified. Bacillus sp. 475B was non-cytotoxic, non-hemolytic, and susceptible to most tested antibiotics. The strain tolerated low pH, bile salts, high salinity, and high temperatures, as well as the capacity to adhere to the jejunum of healthy mice determined by fluorescence microscopy. Supernatants from cultures at 30 and 50 °C inhibited the growth of methicillin-resistant Staphylococcus aureus (MRSA). In vivo enhanced immune responses as indicated by increased nitric oxide production and myeloperoxidase activity. Antibody levels were not affected by supplementation with the strain. These findings highlight the potential of Bacillus sp. 475B is a robust and functional probiotic candidate for future applications in health and biotechnology.
Indexed as
Identifiers
41627459What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.